Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Pharmacologic Therapies for Sickle Cell Disease
source: Journal of Sickle Cell Disease and Hemoglobinopathies (JSCDH)
year: 2016
authors: Lanetta Bronte, Kenneth I. Ataga, Kenneth Ataga, Lakiea, Bailey, Iris Buchanan, Gregory Kato, Ify Osunkwo, Betty Pace
summary/abstract:Sickle cell disease (SCD) is a multisystem disease, associated with episodes of acute illness and progressive organ damage. Despite its low prevalence in the United States, SCD is one of the most common severe monogenic disorders worldwide, with an estimated 230,000 affected children born every year in sub-Saharan Africa. As a result of its multiple complications, SCD is associated with an overall decreased life expectancy. In addition, the economic burden of SCD is enormous – a consequence of recurrent and chronic SCD-related complications, frequent absences from school and work, and physical impairment limiting the ability to contribute to society.
Although there is an increased understanding of the pathophysiology of SCD, available pharmacologic treatments remain limited. The current approach to the management of SCD includes supportive treatments with folic acid; symptomatic treatment with analgesics, intravenous fluids, oxygen and red blood cell (RBC) transfusion; disease-modifying treatment with hydroxyurea and RBC transfusion; and curative therapy with bone marrow transplantation. Despite the success of bone marrow transplantation as a curative approach in SCD, this modality is limited by its high cost, decreased availability of suitable donors and toxicity.
read more
+myBinderRelated Content
-
Improving vaso-occlusive crisis (VOC) management for those living with sickle cell diseaseThe Sickle Cell Disease Council For CHAN...
-
Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell diseaseEffective medical management for sickle ...
-
New Method of Creating Healthy Stem Cells Could Potentially Improve Treatment of Sickle Cell AnemiaResearchers at New York’s Weill Cornel...
-
Sickle cell warrior documentaryhttps://www.youtube.com/watch?v=ZxC4vtN2...
-
Statement on NHLBI Decision to Pause the Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for Si...bluebird bio, Inc. suspended its clinica...
-
Potential treatment targeting nitric oxide levels, olinciguat, named orphan drug by FDAThe U.S. Food and Drug Administration ...
-
Emmaus Life Sciences, Inc. to present results of phase 3 study of endariTM (L-glutamine oral powder) at 59th America...Emmaus will present results of a Phase 3...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.